These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9085281)

  • 41. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
    Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
    Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
    Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
    Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Evaluation of the efficacy of long-acting somatostatin analog as adjunctive therapy in patients with active acromegaly].
    Gołkowski F; Buziak-Bereza M; Huszno B
    Przegl Lek; 2006; 63(3):117-22. PubMed ID: 16967698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide.
    Tumiati MN; Facchi E; Gatti C; Bossi A; Longari V
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):98-100. PubMed ID: 9002761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
    Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
    Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
    Kurahashi K; Endo I; Kondo T; Morimoto K; Yoshida S; Kuroda A; Aihara KI; Matsuhisa M; Nakajima K; Mizobuchi Y; Nagahiro S; Abe M; Fukumoto S
    Intern Med; 2017 Sep; 56(18):2455-2461. PubMed ID: 28824054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.
    Scheidhauer K; Hildebrandt G; Luyken C; Schomäcker K; Klug N; Schicha H
    Horm Metab Res Suppl; 1993; 27():59-62. PubMed ID: 8330874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues.
    Lauriero F; Pierangeli E; Rubini G; Resta M; D'Addabbo A
    Nucl Med Commun; 1998 Dec; 19(12):1127-34. PubMed ID: 9885802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly.
    Heck A; Emblem KE; Casar-Borota O; Ringstad G; Bollerslev J
    Endocrine; 2016 Jul; 53(1):327-30. PubMed ID: 26615593
    [No Abstract]   [Full Text] [Related]  

  • 53. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses.
    de Herder WW; Lamberts SW
    Curr Opin Oncol; 2002 Jan; 14(1):53-7. PubMed ID: 11790981
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient.
    Resmini E; Dadati P; Ravetti JL; Zona G; Spaziante R; Saveanu A; Jaquet P; Culler MD; Bianchi F; Rebora A; Minuto F; Ferone D
    J Clin Endocrinol Metab; 2007 May; 92(5):1592-9. PubMed ID: 17311860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Somatostatin analogs in the treatment of acromegaly.
    Lamberts SW; Reubi JC; Krenning EP
    Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Somatostatin receptor imaging in CNS tumours using 111In-octreotide.
    Maini CL; Sciuto R; Tofani A; Ferraironi A; Carapella CM; Occhipinti E; Mottolese M; Crecco M
    Nucl Med Commun; 1995 Sep; 16(9):756-66. PubMed ID: 7478408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide.
    Takei M; Suzuki M; Kajiya H; Ishii Y; Tahara S; Miyakoshi T; Egashira N; Takekoshi S; Sanno N; Teramoto A; Osamura RY
    Endocr Pathol; 2007; 18(4):208-16. PubMed ID: 17987403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
    Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
    J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.